LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
![ASCO-GI 2021: [VIRTUAL] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.](https://larvolclin.s3.us-west-2.amazonaws.com/resize_16206080921308275236098845c20171.jpeg "ASCO-GI 2021: [VIRTUAL] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.")
ASCO-GI 2021: [VIRTUAL] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
BRCA, HRR Deficiency, and PARP Inhibitors - ppt download
Expanding PARP Inhibitor Benefits in Advanced Pancreatic Cancer | MedPage Today
NCCN Guidelines Updates: Pancreatic Cancer in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 5.5 (2019)
Cancer Trial Results
New Homologous Recombination Deficiency Findings in Pancreatic Cancer Alter Treatment Focus
ASCO GI 2021: Results From the Phase 3 POLO Trial
FORCE Blog | New PARP Inhibitor Approval for Pancreatic Cancer
HCP's Thoughts On Pancreatic Cancer | Knowledge | CREATION.co
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
A trial of olaparib for pancreatic cancer that has spread (POLO) | Cancer Research UK
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
POLO trial is back | OS is negative | But the manuscript is full SPIN CYCLE | Insane! - YouTube
Maintenance rucaparib shows benefit in broader group of patients with pancreatic cancer
Olaparib in Metastatic Pancreatic Cancer
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
Sotorasib in KRAS p.G12C-mutated Pancreatic Cancer
Dr Amol Akhade on Twitter: "19 vs 19.2 . POLO . Metastatic pancrease ca. Once again Placebo arm has longer OS than Olaparib. I really appreciate the positive spin off by medical
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
